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Introduction {#jah32019-sec-0005}
============

The suppression of tumorigenicity 2 (ST2) receptor is a member of the interleukin‐1 family of receptors and exists as transmembrane (ST2L) and soluble (sST2) isoforms differentially regulated by alternative splicing.[1](#jah32019-bib-0001){ref-type="ref"}, [2](#jah32019-bib-0002){ref-type="ref"} Interleukin‐33 (IL‐33) binds to ST2L to elicit downstream signaling, whereas sST2 acts as a nonfunctional decoy IL‐33 receptor, limiting IL‐33/ST2L signaling.[3](#jah32019-bib-0003){ref-type="ref"} In patients with autoimmune inflammatory conditions, sST2 levels are elevated; in related experimental models, IL‐33/ST2L signaling is proinflammatory and exacerbates clinical severity, whereas sST2 administration abrogates IL‐33/ST2L signaling and is protective.[3](#jah32019-bib-0003){ref-type="ref"}, [4](#jah32019-bib-0004){ref-type="ref"} In contrast, in cardiomyocytes and experimental heart failure (HF), IL‐33/ST2L signaling is activated with cardiomyocyte/cardiac mechanical stress and neurohumoral activation but exerts protective cardiac antiremodeling effects. In these models, sST2 administration worsens the cardiac phenotype.[4](#jah32019-bib-0004){ref-type="ref"}, [5](#jah32019-bib-0005){ref-type="ref"}

Although elevated sST2 levels have been repeatedly shown to be associated with worse outcomes in HF with reduced ejection fraction (HFrEF),[6](#jah32019-bib-0006){ref-type="ref"}, [7](#jah32019-bib-0007){ref-type="ref"}, [8](#jah32019-bib-0008){ref-type="ref"}, [9](#jah32019-bib-0009){ref-type="ref"}, [10](#jah32019-bib-0010){ref-type="ref"}, [11](#jah32019-bib-0011){ref-type="ref"}, [12](#jah32019-bib-0012){ref-type="ref"}, [13](#jah32019-bib-0013){ref-type="ref"}, [14](#jah32019-bib-0014){ref-type="ref"}, [15](#jah32019-bib-0015){ref-type="ref"}, [16](#jah32019-bib-0016){ref-type="ref"} sST2 appears to be of extracardiac origin in HFrEF.[17](#jah32019-bib-0017){ref-type="ref"}, [18](#jah32019-bib-0018){ref-type="ref"}, [19](#jah32019-bib-0019){ref-type="ref"}, [20](#jah32019-bib-0020){ref-type="ref"} To date, sST2 has not been well studied in HF with preserved ejection fraction (HFpEF). In HFpEF, comorbidity‐driven microvascular endothelial inflammation may play a key role in the genesis of myocardial, vascular, skeletal muscle, and other end‐organ damage,[21](#jah32019-bib-0021){ref-type="ref"}, [22](#jah32019-bib-0022){ref-type="ref"}, [23](#jah32019-bib-0023){ref-type="ref"}, [24](#jah32019-bib-0024){ref-type="ref"}, [25](#jah32019-bib-0025){ref-type="ref"} and IL‐33/ST2 signaling appears to be involved in vascular endothelial cell inflammation and remodeling.[17](#jah32019-bib-0017){ref-type="ref"}, [26](#jah32019-bib-0026){ref-type="ref"}, [27](#jah32019-bib-0027){ref-type="ref"} Furthermore, once established, HF may itself perpetuate inflammation in proportion to the severity of systemic congestion and hypoperfusion.[28](#jah32019-bib-0028){ref-type="ref"}, [29](#jah32019-bib-0029){ref-type="ref"} Thus, sST2 may be elevated in HFpEF caused by cardiomyocyte stress, comorbidity‐driven systemic inflammation, or inflammation related to the severity of HF. Accordingly, in the comprehensively characterized HFpEF patients enrolled in the Phosphodiesterase‐5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) trial,[30](#jah32019-bib-0030){ref-type="ref"} we determined whether circulating sST2 (henceforth ST2) levels were associated with the severity of cardiac remodeling and dysfunction, proinflammatory comorbidities, or markers of clinical HF severity.

Methods {#jah32019-sec-0006}
=======

The RELAX trial was conducted by the Heart Failure Clinical Research Network (HFN) and funded by the National Heart, Lung, and Blood Institute.[30](#jah32019-bib-0030){ref-type="ref"} All patients provided written informed consent, and the trial was approved by the institutional review board at each participating site.

The design, entry criteria, and results of the RELAX trial were reported previously.[30](#jah32019-bib-0030){ref-type="ref"}, [31](#jah32019-bib-0031){ref-type="ref"} Briefly, RELAX enrolled 216 outpatients who had ejection fraction ≥50% and objective evidence of HF. In addition, patients were required to have elevated N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP; ≥400 pg/mL) or elevated invasively measured filling pressures and reduced exercise capacity (≤60% age, sex, and body size--specific predicted peak oxygen consumption). Patients with an estimated glomerular filtration rate (Modification of Diet in Renal Disease equation) \<20 mL/min per 1.73 m^2^ were ineligible.

Participants underwent baseline studies that included a history and physical examination, echocardiography, cardiac magnetic resonance imaging if in sinus rhythm (n=115), cardiopulmonary exercise test, 6‐minute walk test, Minnesota Living with Heart Failure Questionnaire, and phlebotomy for biomarker measurements.[31](#jah32019-bib-0031){ref-type="ref"}

Comprehensive Doppler echocardiography and cardiac magnetic resonance imaging were performed according to study protocols[32](#jah32019-bib-0032){ref-type="ref"} with measurements performed at the HFN echocardiography (Mayo Clinic, Rochester, MN) and cardiac magnetic resonance imaging (Duke University, Durham, NC) core laboratories. The cardiopulmonary exercise test was performed according to a RELAX‐specific protocol and interpreted by the HFN cardiopulmonary exercise test core laboratory (Massachusetts General Hospital, Boston, MA), as reported previously.[31](#jah32019-bib-0031){ref-type="ref"} Biomarker measurements were performed by the HFN biomarker core laboratory (University of Vermont, Burlington, VT), as described previously[30](#jah32019-bib-0030){ref-type="ref"}, [31](#jah32019-bib-0031){ref-type="ref"} and included NT‐proBNP, aldosterone, endothelin‐1, cystatin‐C, creatinine, uric acid, pro--collagen III N‐terminal peptide, C‐telopeptide for type I collagen, high‐sensitivity troponin I, and high‐sensitivity C‐reactive protein. ST2 levels were measured on banked samples by a high‐sensitivity sandwich monoclonal immunoassay (Presage^®^ ST2 assay; Critical Diagnostics). The normal values for ST2 are somewhat controversial, but in a carefully screened healthy Austrian cohort with normal inflammatory markers (C‐reactive protein, procalcitonin, and interleukin‐6) and normal BNP, sex‐specific normal ranges were 4 to 31 ng/mL for male participants and 2 to 21 ng/mL for female participants using the Presage^®^ ST2 assay.[33](#jah32019-bib-0033){ref-type="ref"}

Statistical Analysis {#jah32019-sec-0007}
--------------------

Data are presented as median (25th--75th percentiles) or number (percentage) across ST2 tertiles. Differences across ST2 tertiles were tested with Kruskal--Wallis, χ^2^, or Fisher exact tests, as appropriate. In healthy persons, ST2 levels are higher in men than in women but are not associated with age, body mass index, or renal function.[33](#jah32019-bib-0033){ref-type="ref"}, [34](#jah32019-bib-0034){ref-type="ref"} Thus, multivariable least squares linear or logistic regression was used to assess the relationship between variables of interest and ST2 as a categorical variable (tertiles) adjusting for sex. With our sample size, we had 84% and 92% power to detect correlations of 0.22 and 0.25, respectively, between ST2 and other continuous measures. The associations between ST2 (log transformed) and other biomarkers (log transformed) are presented with Pearson correlation coefficients and were tested using linear regression models without and with sex adjustment. Analyses were performed by the HFN data coordinating center using SAS version 9.4 (SAS Institute). A *P*\<0.05 (2‐sided) was considered statistically significant.

Results {#jah32019-sec-0008}
=======

Of the 216 participants enrolled in RELAX, stored serum from 174 patients was available to measure ST2 at enrollment. Included participants had a median age of 69 years, and 52% were men. Participants without stored serum availability were more likely to have had a HF hospitalization, worse renal function, and higher NT‐proBNP levels (Table [S1](#jah32019-sup-0001){ref-type="supplementary-material"}).

The median ST2 levels were 34.3 ng/mL (25th--75th percentiles 26.9--46.6 ng/mL) with a range from 14.4 to 197.9 ng/mL and higher levels in male participants (median 36.7 ng/mL \[25th--75th percentiles 30.9--49.2 ng/mL\]) than in female participants (median 30.8 ng/mL \[25th--75th percentiles 25.3--39.3 ng/mL\]) (Figure [1](#jah32019-fig-0001){ref-type="fig"}, Table [1](#jah32019-tbl-0001){ref-type="table-wrap"}). Accordingly, all results described in the following sections were adjusted for sex.

![Frequency distribution of suppression of tumorigenicity 2 (ST2) levels in heart failure with preserved ejection fraction overall and by sex (insert). The distribution of baseline ST2 levels in the RELAX trial cohort (n=174). Overall, median ST2 levels were 34.3 ng/mL (25th--75th percentiles 26.9--46.6 ng/mL) and were higher in male participants (36.7 ng/mL \[25th--75th percentiles 30.9--49.2 ng/mL\]) than in female participants (30.8 ng/mL \[25th--75th percentiles 25.3--39.3 ng/mL\]).](JAH3-6-e004382-g001){#jah32019-fig-0001}

###### 

Baseline Patient Characteristics by Tertiles of Baseline ST2 Levels

                                   Low ST2 Tertile (n=58)   Mid ST2 Tertile (n=58)   High ST2 Tertile (n=58)   *P* Value   *P* Value[a](#jah32019-note-0003){ref-type="fn"}
  -------------------------------- ------------------------ ------------------------ ------------------------- ----------- --------------------------------------------------
  ST2 range, ng/mL                 \<29.5                   29.5--38.5               \>38.5                    ...         ...
  ST2, ng/mL                       23.8 (21.7--26.9)        34.3 (31.6--36.5)        51.1 (46.6--66.4)         ...         ...
  Male                             18 (31)                  32 (55)                  36 (62)                   0.002       ...
  Age, y                           67 (61--74)              71 (64--79)              69 (63--77)               0.16        0.30
  Body mass index, kg/m^2^         32.9 (28.6--36.9)        32.5 (28.0--38.8)        33.8 (28.6--40.1)         0.54        0.70
  Body surface area, m^2^          2.13 (1.95--2.23)        2.07 (1.89--2.39)        2.12 (1.95--2.29)         0.80        0.53
  HF hospitalization               18 (31)                  16 (28)                  21 (36)                   0.60        0.63
  Comorbidities                                                                                                            
  Hypertension                     44 (76)                  56 (97)                  46 (79)                   0.005       0.023
  Ischemic heart disease           20 (34)                  20 (34)                  27 (47)                   0.30        0.50
  Atrial fibrillation              21 (36)                  30 (52)                  34 (59)                   0.047       0.049
  COPD                             8 (14)                   11 (19)                  13 (22)                   0.48        0.77
  Diabetes mellitus                17 (29)                  19 (33)                  35 (60)                   0.001       0.005
  Creatinine, mg/dL (n=172)        1.0 (0.8--1.3)           1.0 (0.9--1.2)           1.2 (0.9--1.7)            0.016       0.018
  Cystatin‐C, mg/L                 1.15 (0.92--1.46)        1.21 (1.08--1.47)        1.58 (1.13--2.15)         0.0003      \<0.0001
  Medications                                                                                                              
  ACEI or ARB                      40 (69)                  41 (71)                  35 (60)                   0.45        0.36
  Aldosterone antagonist           5 (9)                    6 (10)                   8 (14)                    0.66        0.62
  Beta blocker                     40 (69)                  42 (72)                  45 (78)                   0.57        0.80
  Loop diuretic                    36 (62)                  43 (74)                  51 (88)                   0.006       0.013
  Congestion and quality of life                                                                                           
  NT‐proBNP, pg/mL (n=173)         382 (94--656)            696 (356--1621)          955 (497--1802)           \<0.0001    \<0.0001
  Elevated JVP (n=168)             16 (28)                  24 (44)                  33 (59)                   0.004       0.003
  Moderate or severe edema         5 (9)                    8 (14)                   22 (38)                   0.0006      0.0006
  NYHA class II                    35 (60)                  26 (45)                  24 (41)                   0.09        0.029
  MLHFQ score (n=166)              37 (30--63)              49 (35--65)              44 (25--60)               0.16        0.17

Values are median (interquartile range) or n (%). ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; HF, heart failure; JVP, jugular venous pressure; MLHFQ, Minnesota Living with Heart Failure Questionnaire; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; ST2, suppression of tumorigenicity 2.

Adjusted for sex.

Clinical Characteristics and ST2 Levels in HFpEF {#jah32019-sec-0009}
------------------------------------------------

There was no association between ST2 levels and age, body size, or history of HF hospitalization (Table [1](#jah32019-tbl-0001){ref-type="table-wrap"}). However, patients with higher ST2 levels were more likely to have diabetes mellitus (*P*=0.005), hypertension (*P*=0.023), atrial fibrillation or flutter (*P*=0.049), and renal dysfunction (*P*\<0.0001) and were more likely to be treated with diuretics (*P*=0.013). Lung disease prevalence was similar across ST2 tertiles. Patients with higher ST2 levels also had more congestion with higher NT‐proBNP levels (*P*\<0.0001), a higher prevalence of jugular venous pressure elevation (*P*=0.003), more peripheral edema (*P*=0.0006), and worse New York Heart Association functional class (*P*=0.029), although ST2 levels were not associated with the Minnesota Living with Heart Failure Questionnaire score (Table [1](#jah32019-tbl-0001){ref-type="table-wrap"}).

Exercise Performance and ST2 Levels in HFpEF {#jah32019-sec-0010}
--------------------------------------------

Six‐minute walk distance (*P*=0.012), peak oxygen consumption (*P*=0.017), percentage of predicted peak oxygen consumption (*P*=0.017), and peak systolic blood pressure (*P*=0.005) all declined with increasing ST2 levels (Table [2](#jah32019-tbl-0002){ref-type="table-wrap"}). There were nonsignificant trends toward lower peak heart rate (*P*=0.07) and chronotropic index (*P*=0.08) despite similar effort, as reflected in the respiratory exchange ratio. There was no association between ST2 levels and ventilatory efficiency (VE/VCO~2~ slope).

###### 

Exercise Performance by Tertile of Baseline ST2 Levels

                                 Low ST2 Tertile (n=58)   Mid ST2 Tertile (n=58)   High ST2 Tertile (n=58)   *P* Value   *P* Value[a](#jah32019-note-0005){ref-type="fn"}
  ------------------------------ ------------------------ ------------------------ ------------------------- ----------- --------------------------------------------------
  Peak VO~2~, mL/kg per minute   12.1 (10.9--14.4)        11.9 (10.8--15.1)        11.2 (10.0--13.3)         0.12        0.017
  Peak VO~2~, % predicted        44 (38--51)              42 (35--48)              39 (32--47)               0.024       0.017
  Respiratory exchange ratio     1.11 (1.05--1.17)        1.09 (1.03--1.15)        1.09 (1.02--1.15)         0.41        0.41
  Peak systolic BP, mm Hg        160 (140--184)           154 (138--168)           148 (126--168)            0.07        0.005
  Rest HR, bpm                   67 (59--76)              70 (60--75)              69 (61--79)               0.58        0.43
  Peak HR, bpm                   111 (96--136)            107 (91--120)            107 (91--128)             0.12        0.07
  Chronotropic index             0.55 (0.38--0.71)        0.47 (0.29--0.62)        0.49 (0.28--0.69)         0.15        0.08
  VE/VCO~2~ slope                31.7 (28.1--36.9)        33.8 (28.6--37.5)        34.9 (31.0--39.9)         0.06        0.20
  6‐minute walk distance, m      351 (265--434)           305 (244--372)           311 (230--360)            0.046       0.012

Total sample size with data (N=168--174). BP indicates blood pressure; bpm, beats per minute; HR, heart rate; ST2, suppression of tumorigenicity 2; VE/VCO~2~, ventilatory efficiency; VO~2~, oxygen consumption.

Adjusted for sex.

Cardiac Structure and Function and ST2 Levels in HFpEF {#jah32019-sec-0011}
------------------------------------------------------

There were no associations between ST2 levels and left ventricular (LV) diastolic or systolic function parameters or LV geometry as assessed by echocardiography (Table [3](#jah32019-tbl-0003){ref-type="table-wrap"}) or in patients in sinus rhythm, by cardiac magnetic resonance (Table [S2](#jah32019-sup-0001){ref-type="supplementary-material"}). Participants with higher ST2 levels had higher right ventricular (RV) systolic pressure (*P*=0.016) and worse RV function (lower tricuspid annular plane systolic excursion, *P*=0.015) by echocardiography (Table [3](#jah32019-tbl-0003){ref-type="table-wrap"}). In contrast, NT‐proBNP levels were strongly associated with all diastolic function parameters, LV geometry, and RV load and systolic function but not with LV ejection fraction (Table [S3](#jah32019-sup-0001){ref-type="supplementary-material"}).

###### 

Baseline Cardiac Structure and Function by Tertiles of Baseline ST2 Levels

                                                    N[a](#jah32019-note-0007){ref-type="fn"}   Low ST2 Tertile (n=58)   Mid ST2 Tertile (n=58)   High ST2 Tertile (n=58)   *P* Value   *P* Value[b](#jah32019-note-0008){ref-type="fn"}
  ------------------------------------------------- ------------------------------------------ ------------------------ ------------------------ ------------------------- ----------- --------------------------------------------------
  Diastolic function parameters                                                                                                                                                        
  E/A ratio                                         118                                        1.4 (1.0--1.9)           1.3 (0.9--3.0)           1.6 (1.0--3.0)            0.70        0.68
  Medial e′, m/s                                    160                                        0.06 (0.04--0.07)        0.07 (0.05--0.08)        0.06 (0.05--0.08)         0.56        0.77
  Medial E/e′                                       155                                        14.9 (11.3--22.0)        15.0 (10.0--20.0)        17.9 (13.1--24.5)         0.17        0.14
  Deceleration time, ms                             159                                        192 (159--215)           180 (158--219)           181 (151--219)            0.86        0.97
  LA volume/BSA, mL/m^2^                            123                                        41 (33--50)              47 (34--62)              51 (35--62)               0.08        0.16
  Left ventricular systolic function and geometry                                                                                                                                      
  Ejection fraction, %                              173                                        61 (57--66)              61 (56--66)              60 (55--63)               0.29        0.47
  LVEDd/BSA, cm/m^2^                                133                                        2.3 (2.1--2.5)           2.2 (2.0--2.4)           2.2 (2.0--2.5)            0.58        0.91
  Relative wall thickness                           128                                        0.38 (0.34--0.44)        0.42 (0.36--0.52)        0.42 (0.37--0.46)         0.06        0.10
  LV mass/BSA, g/m^2^                               128                                        76 (64--85)              72 (61--89)              80 (60--100)              0.98        0.60
  Right ventricular load and function                                                                                                                                                  
  PASP, mm Hg                                       113                                        39 (32--48)              46 (34--58)              43 (32--51)               0.045       0.016
  TAPSE, mm                                         172                                        19.0 (16.0--23.0)        17.5 (14.0--24.0)        16.0 (13.0--20.0)         0.013       0.015
  Vascular function                                                                                                                                                                    
  Systolic BP, mm Hg                                174                                        128 (114--140)           123 (113--137)           124 (112--131)            0.44        0.25
  Diastolic BP, mm Hg                               174                                        70 (64--80)              70 (62--78)              69 (62--78)               0.66        0.50
  Ao distensibility, 10^−3^ mm Hg^−1^               68                                         1.21 (0.67--1.46)        1.08 (0.58--2.25)        1.09 (0.67--1.76)         0.77        0.50

Data are median (interquartile range). Ao indicates aortic; BP, blood pressure; BSA, body surface area; LA, left atrial; LV, left ventricular; LVEDd, left ventricular end‐diastolic dimension; PASP, pulmonary artery systolic pressure; ST2, suppression of tumorigenicity 2; TAPSE, tricuspid annular plane systolic excursion.

Total sample with data.

Adjusted for sex.

ST2 and Other Biomarkers in HFpEF {#jah32019-sec-0012}
---------------------------------

ST2 concentrations were correlated with endothelin‐1 (*r*=0.33, *P*\<0.0001) and with biomarkers of systemic inflammation (high‐sensitivity C‐reactive protein, *r*=0.22, *P*=0.002), fibrosis (C‐telopeptide for type I collagen, *r*=0.30, *P*=0.0004), and myocardial necrosis (high‐sensitivity troponin‐I, *r*=0.33, *P*\<0.0001) but not with aldosterone or pro--collagen III N‐terminal peptide (Figure [2](#jah32019-fig-0002){ref-type="fig"}).

![The relationship between suppression of tumorigenicity 2 (ST2) and biomarkers in heart failure with preserved ejection fraction. ST2 was associated with endothelin 1, high‐sensitivity C‐reactive protein (CRP), C‐telopeptide for type I collagen (CITP), and troponin I but not aldosterone or pro--collagen III N‐terminal peptide (PIIINP) levels. \*Adjusted for sex. Ln indicates log transformed.](JAH3-6-e004382-g002){#jah32019-fig-0002}

Discussion {#jah32019-sec-0013}
==========

In this comprehensively phenotyped cohort of patients with HFpEF, ST2 levels were elevated compared with published normative sex‐specific values. ST2 was higher in the presence of several proinflammatory comorbidities (diabetes mellitus, atrial fibrillation, renal dysfunction) and associated with greater RV pressure overload and dysfunction; central venous congestion; exercise intolerance; and biomarkers reflective of systemic inflammation and fibrosis, neurohumoral activation, and myocardial necrosis. ST2 levels were not associated with LV geometry or LV systolic or diastolic function. In contrast, NT‐proBNP---a biomarker of myocardial origin, the production of which is stimulated by wall stress---correlated with the severity of LV remodeling and diastolic dysfunction. These data add to our understanding of ST2 in HFpEF and suggest that in HFpEF, ST2 is predominately a marker of systemic inflammation activated by interplay between proinflammatory comorbidities and HF severity--related systemic congestion.

Association of ST2 Levels With Sex {#jah32019-sec-0014}
----------------------------------

Consistent with findings in other cohorts,[33](#jah32019-bib-0033){ref-type="ref"}, [34](#jah32019-bib-0034){ref-type="ref"}, [35](#jah32019-bib-0035){ref-type="ref"} male RELAX participants had higher ST2 levels than their female counterparts. Although the mechanism of sex differences in ST2 levels remains unclear, the considerable differences of ST2 levels between sexes warrant adjustment for sex when analyzing the association between ST2 levels and disease severity.[36](#jah32019-bib-0036){ref-type="ref"}

ST2 as a Biomarker in HFpEF {#jah32019-sec-0015}
---------------------------

Despite the lower percentage of male participants in RELAX compared with studies of ambulatory HFrEF patients, the median level of ST2 in this HFpEF cohort was higher than that observed in studies of ambulatory HFrEF patients[8](#jah32019-bib-0008){ref-type="ref"}, [10](#jah32019-bib-0010){ref-type="ref"} and approached the 33--35 ng/mL cut point associated with a higher risk of cardiovascular outcomes in chronic HFrEF.[8](#jah32019-bib-0008){ref-type="ref"}, [10](#jah32019-bib-0010){ref-type="ref"}, [11](#jah32019-bib-0011){ref-type="ref"} Median ST2 levels in RELAX were also higher than those reported in patients with ischemic heart disease (19--24 ng/mL)[37](#jah32019-bib-0037){ref-type="ref"}, [38](#jah32019-bib-0038){ref-type="ref"} and in the general population (22 ng/mL)[34](#jah32019-bib-0034){ref-type="ref"} but lower than those reported in acute HF or pulmonary disease (42--76 ng/mL)[15](#jah32019-bib-0015){ref-type="ref"}, [33](#jah32019-bib-0033){ref-type="ref"}, [39](#jah32019-bib-0039){ref-type="ref"} and much lower than observed in critically ill intensive care unit patients (555--745 ng/mL).[33](#jah32019-bib-0033){ref-type="ref"}, [40](#jah32019-bib-0040){ref-type="ref"} Importantly, all of these studies used the same Presage^®^ ST2 assay. Although relatively few studies have evaluated ST2 levels in HFpEF,[6](#jah32019-bib-0006){ref-type="ref"}, [18](#jah32019-bib-0018){ref-type="ref"}, [35](#jah32019-bib-0035){ref-type="ref"} the only one to assess ST2 using this assay was a post hoc analysis of the PARAMOUNT (Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction) trial that described elevated median ST2 levels (33 ng/mL), similar to the HFpEF patients in RELAX.[35](#jah32019-bib-0035){ref-type="ref"}

Association of ST2 Levels With Clinical Characteristics {#jah32019-sec-0016}
-------------------------------------------------------

The associations we observed between ST2 levels and comorbidities including diabetes mellitus, renal dysfunction, and atrial fibrillation as well as congestion, diuretic use, and New York Heart Association functional status have also been reported in studies of ambulatory patients with HFrEF[8](#jah32019-bib-0008){ref-type="ref"}, [10](#jah32019-bib-0010){ref-type="ref"}, [11](#jah32019-bib-0011){ref-type="ref"} and the PARAMOUNT HFpEF cohort.[35](#jah32019-bib-0035){ref-type="ref"} Diabetes mellitus, renal dysfunction, atrial fibrillation, and chronic venous congestion are all linked to inflammation.[41](#jah32019-bib-0041){ref-type="ref"} It is perhaps surprising that obesity was not associated with ST2 levels in this cohort or in the PARAMOUNT HFpEF cohort,[35](#jah32019-bib-0035){ref-type="ref"} given a previous study showing higher ST2 levels in severe obesity and the known proinflammatory effect of obesity.[42](#jah32019-bib-0042){ref-type="ref"} However, the intensity and types of inflammation linked to activation of ST2 are not well defined.[33](#jah32019-bib-0033){ref-type="ref"} It is important to note that ST2 levels are not associated with renal function in the general population[34](#jah32019-bib-0034){ref-type="ref"} or elevated in a small sample of chronic kidney disease patients without HF,[33](#jah32019-bib-0033){ref-type="ref"} suggesting a unique interaction among HF, renal dysfunction, and ST2 levels.

Association of ST2 Levels With Functional Capacity {#jah32019-sec-0017}
--------------------------------------------------

In HFpEF, as in HFrEF, ST2 levels were associated with worse exercise capacity. Because skeletal muscle function is a potent determinant of peak oxygen consumption in HFpEF,[25](#jah32019-bib-0025){ref-type="ref"} this association may reflect effects of systemic inflammation on skeletal muscle or peripheral vascular function, given the lack of association of ST2 and resting LV structure and function.

Association of ST2 Levels With Cardiac Structure and Function {#jah32019-sec-0018}
-------------------------------------------------------------

Although an association between ST2 and ventricular dysfunction was demonstrated in animal studies,[4](#jah32019-bib-0004){ref-type="ref"} a relationship between circulating ST2 levels and the severity of cardiac remodeling or dysfunction in clinical HF is less clear.[8](#jah32019-bib-0008){ref-type="ref"}, [35](#jah32019-bib-0035){ref-type="ref"}, [43](#jah32019-bib-0043){ref-type="ref"}, [44](#jah32019-bib-0044){ref-type="ref"}, [45](#jah32019-bib-0045){ref-type="ref"}

In general population cohorts with a spectrum of LV geometry and function, ST2 levels were not associated with LV mass[46](#jah32019-bib-0046){ref-type="ref"} or ejection fraction[47](#jah32019-bib-0047){ref-type="ref"}, [48](#jah32019-bib-0048){ref-type="ref"} but were associated with a greater likelihood of asymptomatic diastolic dysfunction in one study.[47](#jah32019-bib-0047){ref-type="ref"} In a diverse cohort of patients evaluated in an emergency department for dyspnea and subsequently found to have HFrEF, HFpEF, or noncardiac dyspnea, ST2 levels were higher in HF than noncardiac dyspnea and, across the combined HF groups, were associated with LV ejection fraction, RV systolic dysfunction, higher pulmonary artery pressures, and more severe tricuspid regurgitation but not with LV mass or diastolic function.[43](#jah32019-bib-0043){ref-type="ref"} In another study of patients with acute dyspnea and normal ejection fraction (most with noncardiac dyspnea), ST2 was not associated with LV mass or most Doppler measures of diastolic function.[44](#jah32019-bib-0044){ref-type="ref"} ST2 levels were not meaningfully associated with LV remodeling in HFrEF.[8](#jah32019-bib-0008){ref-type="ref"} The PARAMOUNT analysis in HFpEF found a modest association of ST2 levels with left atrial volumes but no other parameter of cardiac structure or function, although RV indices were not assessed.[35](#jah32019-bib-0035){ref-type="ref"}

In the RELAX HFpEF cohort, we found no association between LV structure or function and ST2 levels, whereas NT‐proBNP (of myocardial origin[20](#jah32019-bib-0020){ref-type="ref"}) was strongly associated with cardiac structure and function. The association of ST2 levels with RV function observed in this study may be related to the impact of RV dysfunction on systemic venous congestion and its known proinflammatory effects.[29](#jah32019-bib-0029){ref-type="ref"}

Mechanism of ST2 Activation in HFpEF {#jah32019-sec-0019}
------------------------------------

We did not measure the transcardiac ST2 gradient, and thus the systemic versus cardiac source of elevated levels of ST2 in HFpEF cannot be established in our study. The lack of a relationship between ST2 and LV structure and function and the associations between ST2 and proinflammatory comorbidities, severity of congestion, and biomarkers reflective of systemic inflammation and fibrosis (high‐sensitivity C‐reactive protein and C‐telopeptide for type I collagen) and myocardial injury or inflammation (high‐sensitivity troponin I) may implicate an extracardiac source of ST2 in HFpEF, as has been established in HFrEF.[17](#jah32019-bib-0017){ref-type="ref"}, [18](#jah32019-bib-0018){ref-type="ref"}, [19](#jah32019-bib-0019){ref-type="ref"}, [20](#jah32019-bib-0020){ref-type="ref"} Indeed, human saphenous venous and arterial endothelial cells exposed to inflammatory stimuli have been shown to secrete ST2,[17](#jah32019-bib-0017){ref-type="ref"}, [18](#jah32019-bib-0018){ref-type="ref"}, [49](#jah32019-bib-0049){ref-type="ref"} and we speculate that that activation of ST2 reflects systemic inflammation in HFpEF. Whether the inflammatory stimulus putatively responsible for ST2 activation is mediated by comorbidity‐driven microvascular endothelial inflammation or the systemic congestion and end‐organ hypoperfusion common to advanced HFpEF or HFrEF is deserving of further study.

Limitations {#jah32019-sec-0020}
-----------

Given the post hoc nature of this study and its modest sample size, this analysis was deemed to be exploratory with the aim of generating hypotheses that could be tested in larger mechanistic HFpEF studies. The RELAX cohort had relatively advanced HFpEF,[30](#jah32019-bib-0030){ref-type="ref"}, [50](#jah32019-bib-0050){ref-type="ref"} and this may limit correlations, although the range of ST2 levels was fairly broad. Those patients missing stored serum appeared to have more severe HF; some associations may have been stronger if the entire cohort had available serum. The association of ST2 levels and outcomes was not assessed in RELAX, given the short duration of follow‐up.

Conclusion {#jah32019-sec-0021}
==========

In HFpEF, ST2 levels were elevated and associated with proinflammatory comorbidities; RV pressure overload and dysfunction; systemic congestion; exercise intolerance; and biomarkers reflective of systemic inflammation and fibrosis, neurohumoral activation, and myocardial injury but not with LV structure and function. These data add to our understanding of ST2 as a biomarker in HFpEF and suggest that systemic inflammation may mediate or contribute to activation of ST2 in HFpEF.
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